Akeso begins Phase III study of cadonilimab for gastric cancer

Akeso has commenced a global Phase III clinical trial, with the enrolment of the first patient, to evaluate its bispecific antibody, cadonilimab, in treating advanced gastric cancer. The antibody targets patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. The bispecific antibody is intended for treating advanced gastric cancer. Credit: SewCreamStudio/Shutterstock.com. Akeso has commenced a global Phase III clinical trial, with the enrolment of the first patient, to evaluate its bispecific antibody, cadonilimab, in treating advanced gastric cancer. The study, titled COMPASSION-37 (AK104-311), will compare the antibody combined with chemotherapy against chemotherapy with or without nivolumab. LOA and PTSR…

Source: Clinical Trials Arena